https://www.nature.com/articles/d41591-023-00067-x
0
0
7/31/23 at 10:30am
Organization
Nature.com
Authors
The monoclonal antibody donanemab, which clears amyloid plaques in the brain, slowed clinical progression of early symptomatic Alzheimer’s disease.
Create an account
or login to join the discussion